#876
Incidence and Prevalence of Neuroendocrine Tumors (NETs) of the Ileum and Colon (Excluding Appendiceal NETs) in Northern Ireland (NI) Over a 25-Year-Period (1988-2012)
Introduction:
Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
Ardill J
Authors:
Ardill J,
Johnston B,
Stronge W,
Turner G,
McCance D,
Keywords:
MGC,
#616
Assessment of DNA Double-Strand Breaks in Blood Lymphocytes after Whole-Body Radiation Exposure in Patients with Neuroendocrine Tumors Undergoing 177Lu-Octreotate Therapy
Introduction:
Peptide receptor radionuclide therapy using somatostatin receptor-binding peptides, such as 177Lu-Octreotate (LuTate), has been clinically proven to be effective in treating patients with inoperable neuroendocrine tumors. Despite the rather high radiation exposure, only few side effects have been reported. However, blood cells are very sensitive to radiation. Therefore, it is important to determine how much radiation they received. Recently, the detection by immunofluorescence of the phosphorylation of the histone variant H2AX (γ‐H2AX) has been established as a reliable and sensitive technique to monitor DNA double-strand breaks (DSBs) in blood lymphocytes.
Conference:
10th Annual ENETSConcerence (2013)
Presenting Author:
Denoyer D
Authors:
Denoyer D,
Martin O,
Jackson P,
Johnston V,
Hicks R,
Keywords:
177Lu-Octreotate,
γ‐H2AX,
DNA damage,
